Claire-Marie Coste-Lepoutre
Analyst · Bloomberg, and we will read it out on your behalf
Thank you very much, Frank, and good morning, everyone. Let me start with an overview of the group results for the first quarter of 2026. So the overall picture from my perspective is one of a strong start to the year, which allow us to reaffirm our full year outlook of an operating profit of EUR 17.4 billion, plus/minus EUR 1 billion. We can confidently do so despite an elevated market volatility and a more uncertain macro environment. Across our 3 strategic levers: growth, productivity and resilience, we continue to execute with discipline and to deliver towards our ambition. Moving to the numbers on Page A4. Here, you can see, overall, our business volume continues to show steady internal growth, driven in particular this quarter by our P&C and Asset Management segments. The Life business was resilient against the first quarter 2025, where business volume were particularly high back then. Our operating profit momentum is excellent, nearly 7% year-on-year with -- where we see more benefit from the diversification of our business model. Here, we see, in particular, a double-digit growth in P&C, which is reaching a new record level of operating profit, an excellent performance in Asset Management, which is up 6% or 15% if you adjust for FX. And Life delivered a resilient performance even if it has been impacted by FX and the disposal of the joint ventures with UniCredit and Bajaj. Our net income includes the impact of the completion of the Bajaj disposal for EUR 1.1 billion net. As a reminder, we have indicated in the fourth quarter that we will neutralize this accounting gain over the course of 2026 through strategic and productivity actions and reinvestment into higher-yielding instruments. Only a modest offset of EUR 150 million net was booked in the first quarter and more will follow through -- during the year. Adjusted for the Bajaj impacts, our underlying core net income achieved a strong increase of 7% year-on-year with an ROE of 18% and an excellent EPS growth of 9%. So beyond these exceptional effects, the fundamental performance is very strong and fully on track towards the Capital Market Day ambition. Finally, our Solvency II ratio ended the quarter at 221%. This is a very resilient level with well-contained market volatility and consistently delivered strong operating capital generation. Let's move to P&C on Page A5, where you can see, first of all, that our top line momentum continued at a pace that is in line with 2025. Our internal growth is at 7% with a split roughly 50-50 between price and volume. As you can see in the further detailed pages, the growth across the P&C portfolio remains well diversified. Maybe some standout contributors for this quarter, you will see, as an example, that our platform businesses such as Allianz Partners and Direct have been both growing double digit. We have a strong new business in Germany, and we have also selective growth in commercial where pricing meets our hurdle rates. Across the organization, we continue to focus on our growth [ 3-year ] plan, new customer growth, increased cross-selling and churn reduction. Our underwriting profitability is excellent with a combined ratio at 91%, supported by both retail and commercial. This outcome reflects a broadly benign nat cat environment for the quarter, but more importantly, a robust underlying underwriting performance and an ongoing improvement in the expense ratio. The sustained top line momentum and the further improved combined ratio drives our 11% operating profit growth, reaching an excellent EUR 2.4 billion operating profit. The investment result is broadly flat. We also continue to leverage AI across the P&C value chain, as we have been explaining also in the fourth quarter results from marketing and distribution of new business through to claims management. So basically, broadly, the main focus is on customer experience and also distinctiveness of our product offering so that we can fuel our growth trajectory. A couple of examples maybe of what we have further tapped into during the first quarter. As an example, on Allianz Partners, we have onboarded several new large OEMs relationships where we support -- which are fully supported by Agentic AI tools, in particular on the roadside assistance side, which is by significantly scaling our straight-through processing of claims. In Italy, in France, and Spain, as an example, we have AI tools that are supporting our agents to provide training or real-time support in assessing the risk via AI experts, and this is boosting customer service and productivity at the point of sale. Similarly, in commercial, our submission hub allows for a much faster and higher quality answers to submission via preparation, enrichment and best allocation to underwriters. This is generating significant impact both in response time and conversion rate. So overall, I'm very pleased with the P&C performance this quarter. We see good growth, excellent and robust underwriting profitability across both retail and commercial. Let's move to Life & Health on Page A6, where the underlying performance of the segment is, from my perspective, considerably stronger than the headline momentum might suggest. The new business comparison versus previous year is impacted by a very high base in the first quarter 2025, which included large tickets in Germany, strong Thailand sales ahead of regulatory changes in medical -- on medical riders and the UniCredit JV business, which has been disposed in the second half of 2025. Adjusted for those impacts and the FX effects, the underlying new business volumes are slightly up and the new business value is broadly stable with an attractive mix with Protection & Health and unit-linked contributing to 60%. To illustrate a bit some of those strong developments versus last year, in Italy, as an example, the new business value is up, net of minorities and including associated fees, with strong unit-linked growth through financial advisers. New business in Asia, excluding Thailand, is up 12%, and we see a continued strong momentum in Health Germany with a continuing double-digit new business value growth. On the Life CSM development, we can see that despite the lower new business value, the expected in-force return still exceeded the release, generating a healthy 1.7% normalized growth. Our Life operating profit was impacted by FX and the UniCredit and Bajaj -- UniCredit Vita and Bajaj disposals. Adjusting for this, the underlying Life profit was slightly up. So overall, the Life performance has been resilient in the context of a demanding comparison with last year, perimeter changes and the market volatility seen in the quarter. We remain focused on achieving attractive risk return profile on our new business, and we are confident we will deliver in line with our Capital Market Day targets. Moving to Page A7 and the Asset Management business. There, we had an outstanding start to the year against volatile capital markets. Our net inflows in the first quarter reached a record level for the first quarter with strong growth at both PIMCO and AGI. Overall, the net inflows of EUR 45 billion correspond to an annualized organic growth rate of 9%, diversified across regions and asset classes. Some illustration of this. At PIMCO, we see continued strong traction beyond the more traditional fixed income strategies for its expanding active ETF suite and broad-based demand also across Asia and Europe. At AGI, we see inflows across multi-asset, fixed income, equities, and alternatives with new mandate wins in Asia, in particular. The product proposition of our asset managers continues to be strongly supported by our value creation for our customers via our investment performance with at least 90% of outperformance on a 1- and 3-year basis across our third-party AUM. We generated EUR 2.2 billion of revenues, up 12% FX adjusted, driven by the growth of our assets under management. I'm also very pleased with the productivity focus at both asset managers that is evident in an excellent cost/income ratio, delivering more than EUR 850 million of operating profit, up 15% on an FX-adjusted basis. It was a volatile period for capital markets in the first quarter, and there was a lot of debate around topics such as private credit. Overall, our asset management businesses have been selective and very mindful of liquidity considerations even when growing their private and alternative offerings. Their focus in the alternative and private credit space is differentiated and focused around areas such as infrastructure or asset-backed finance. Overall, the current focus on credit and liquidity risk is a tailwind for our asset managers to continue to demonstrate the strength of their offering. Let's move to Page A8, looking at our solvency ratio development. It has now further emerged with a strong solvency ratio at 221% with a 2 percentage point increase versus year-end in a volatile market environment. I think on this page, beyond the announced Bajaj share buyback and the usual dividend accrual effects, the additional interesting points for me are the fact that, first of all, we have a very contained market impact. And secondly, that we have a very consistent operating capital generation. So, clearly, the underlying drivers of the solvency developments are very strong in the quarter with volatility. Let's move to Page A9. Here, I'm very pleased actually to announce that from this quarter onwards, we will be including in the backup slides, actually additional disclosure, providing insights into the performance of our Health & Protection business. As a reminder, we set out a target at the Capital Markets Day to grow the operating profit of Protection & Health by a CAGR of 7% through to 2027 to reach the EUR 2.2 billion operating profit by then. Our Protection & Health business is currently split across P&C and Life segments with different product features, leading to different technical accounting treatments. Our disclosure will develop over time, but it is designed to give more insight into the components of profits and the nature of the products we are selling. On the left-hand side of this slide, we provide some more details on the products in the various segments. This is a broad offering with some key highlights -- highlight products like our new dental offering in Health Germany or our Health Travel coverage at Allianz Partners, both being accounted in different parts of the split between short-term and long-term product. Across the Protection & Health businesses, we combine a strong global oversight on underwriting standards, product and pricing with customization to local market needs. In particular, we have global coordination for our Health business through Allianz Digital Health. This was showcased at our Allianz Insights session of June 2025 and a good reference material from my perspective, if you want to get more insights on our Health business. All our businesses have initiatives in place, as you can see in the middle of this page to further grow and to strengthen technical excellence. Some examples of that will be, as an example, that they cover a broad increased use of digital channels for selling and customer servicing, the use of AI to increase the ability of agents to more quickly educate themselves and to better sell our Health proposition and more systematically leveraging cross-sell opportunities to sell Health alongside our P&C products. Let's move to Page A10, that is actually showing some financial highlights for the business and also illustrate the new format we will use going forward in the backup. You can see the very good momentum in the operating profit, growing 10% year-on-year, adjusted for the disposal of the UniCredit JV. On profitability, you can see a healthy combined ratio of around 93% for the short-term business booked within the P&C business, driven in particular by attractive margins in Health. For the business booked in Life & Health, our new business and new business margin are at a good level but impacted by some scope effects, in particular, the disposal of the UniCredit JV, the lower level of sales of medical riders in Asia and some additional tax on health insurance premiums in France. The normalized CSM growth of around 1.5% for the long-term business is healthy, and we would expect the business to deliver full year normalized growth, at least in line with the whole Life segment. So overall, the Health & Protection market is a huge market with significant growth potential also as we see selective disengagement of states in that space. We see strong appetite for our products also supported by our ecosystems. We are very well positioned and very confident in our ability to meet our Capital Market Day targets here, too. Let me now recap on Page A11. So overall, we had a strong start into the year. If you normalize for the positive effect of the sale of our stake in our JVs with Bajaj, we delivered an excellent 9% core EPS growth, which is at the high end of our Capital Market Day commitments. Similarly, our productivity and resilience focus is as well visible in our numbers. I can just confidently reaffirm our outlook for the full year at EUR 17.4 billion, plus/minus EUR 1 billion. And before I hand over back, Frank, I would like to thank all our employees for their work and their engagement in delivering our results this quarter again. With that, I thank you all for your attention, and I hand over back for questions. Frank?